Oncimmune has entered a contract with a top global pharmaceutical company focused on research on rare immune-related diseases. The pharmaceutical company is reportedly an existing customer of Oncimmune under a long-term master services agreement.

According to the agreement, Oncimmune will provide research services worth USD 700,000 for the pharmaceutical company, including identifying biomarkers related to an undisclosed immune-related disease target or subtype and clinical response. The company anticipates that the new contract will help meet its 2024 financial targets and reach profitability in 2025.

Oncimmune is a precision medicine company specializing in autoantibody profiling and immunodiagnostics. The company's core technology platform, ImmunoINSIGHTS, uses a library of ~9,000 human and multi-species antigens to analyze antibody responses in various biological samples, enabling the discovery of novel biomarkers and providing insights into immune responses. It employs Luminex xMAP technology and is claimed to be able to produce multiplex analysis of hundreds of targets simultaneously using minimal sample volumes (less than 50 μl).